BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Treton X, Bouhnik Y, Mary JY, Colombel JF, Duclos B, Soule JC, Lerebours E, Cosnes J, Lemann M. Azathioprine withdrawal in patients with Crohn’s disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol. 2009;7:80-85. [PMID: 18849016 DOI: 10.1016/j.cgh.2008.08.028] [Cited by in Crossref: 114] [Cited by in F6Publishing: 106] [Article Influence: 8.8] [Reference Citation Analysis]
Number Citing Articles
1 Lakatos PL, Czegledi Z, Szamosi T, Banai J, David G, Zsigmond F, Pandur T, Erdelyi Z, Gemela O, Papp J, Lakatos L. Perianal disease, small bowel disease, smoking, prior steroid or early azathioprine/biological therapy are predictors of disease behavior change in patients with Crohn’s disease. World J Gastroenterol 2009; 15(28): 3504-3510 [PMID: 19630105 DOI: 10.3748/wjg.15.3504] [Cited by in CrossRef: 76] [Cited by in F6Publishing: 81] [Article Influence: 6.3] [Reference Citation Analysis]
2 Danese S, Colombel JF, Reinisch W, Rutgeerts PJ. Review article: infliximab for Crohn's disease treatment--shifting therapeutic strategies after 10 years of clinical experience. Aliment Pharmacol Ther 2011;33:857-69. [PMID: 21320139 DOI: 10.1111/j.1365-2036.2011.04598.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 5.6] [Reference Citation Analysis]
3 Frei P, Biedermann L, Nielsen OH, Rogler G. Use of thiopurines in inflammatory bowel disease. World J Gastroenterol 2013; 19(7): 1040-1048 [PMID: 23467510 DOI: 10.3748/wjg.v19.i7.1040] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
4 Frias Gomes C, Colombel JF, Torres J. De-escalation of Therapy in Inflammatory Bowel Disease. Curr Gastroenterol Rep 2018;20:35. [PMID: 29961926 DOI: 10.1007/s11894-018-0643-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
5 Ye BD, Yang SK, Shin SJ, Lee KM, Jang BI, Cheon JH, Choi CH, Kim YH, Lee H. [Guidelines for the management of Crohn’s disease]. Korean J Gastroenterol. 2012;59:141-179. [PMID: 22387837 DOI: 10.4166/kjg.2012.59.2.141] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
6 Domènech E, Carrión S, Garcia-Planella E, Mañosa M, Gordillo J, Concepción M, Guarner C, Cabré E. Smoking status and response to thiopurines in steroid-dependent inflammatory bowel disease. Inflamm Bowel Dis 2011;17:971-5. [PMID: 20824819 DOI: 10.1002/ibd.21456] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
7 McLean LP, Cross RK. Adverse events in IBD: to stop or continue immune suppressant and biologic treatment. Expert Rev Gastroenterol Hepatol 2014;8:223-40. [PMID: 24490595 DOI: 10.1586/17474124.2014.881715] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 6.7] [Reference Citation Analysis]
8 Kirchgesner J, Beaugerie L, Carrat F, Sokol H, Cosnes J, Schwarzinger M; BERENICE Study Group. Impact on Life Expectancy of Withdrawing Thiopurines in Patients with Crohn's Disease in Sustained Clinical Remission: A Lifetime Risk-Benefit Analysis. PLoS One 2016;11:e0157191. [PMID: 27271176 DOI: 10.1371/journal.pone.0157191] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
9 Boyapati RK, Torres J, Palmela C, Parker CE, Silverberg OM, Upadhyaya SD, Nguyen TM, Colombel JF. Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease. Cochrane Database Syst Rev 2018;5:CD012540. [PMID: 29756637 DOI: 10.1002/14651858.CD012540.pub2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
10 De Cruz P, Kamm MA, Prideaux L, Allen PB, Moore G. Mucosal Healing in Crohnʼs Disease: A Systematic Review. Inflammatory Bowel Diseases 2013;19:429-44. [DOI: 10.1002/ibd.22977] [Cited by in Crossref: 101] [Cited by in F6Publishing: 87] [Article Influence: 12.6] [Reference Citation Analysis]
11 Chouchana L, Narjoz C, Beaune P, Loriot M, Roblin X. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease: Review: pharmacogenetics of thiopurines in IBD. Alimentary Pharmacology & Therapeutics 2012;35:15-36. [DOI: 10.1111/j.1365-2036.2011.04905.x] [Cited by in Crossref: 111] [Cited by in F6Publishing: 96] [Article Influence: 11.1] [Reference Citation Analysis]
12 Kapur S, Hanauer SB. The Evolving Role of Thiopurines in Inflammatory Bowel Disease. Curr Treat Options Gastro 2019;17:435-48. [DOI: 10.1007/s11938-019-00249-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Rohr M, Narasimhulu CA, Sharma D, Doomra M, Riad A, Naser S, Parthasarathy S. Inflammatory Diseases of the Gut. J Med Food 2018;21:113-26. [PMID: 29389238 DOI: 10.1089/jmf.2017.0138] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
14 French H, Mark Dalzell A, Srinivasan R, El-Matary W. Relapse rate following azathioprine withdrawal in maintaining remission for Crohn’s disease: a meta-analysis. Dig Dis Sci. 2011;56:1929-1936. [PMID: 21476031 DOI: 10.1007/s10620-011-1671-5] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
15 Ruemmele F, Veres G, Kolho K, Griffiths A, Levine A, Escher J, Amil Dias J, Barabino A, Braegger C, Bronsky J, Buderus S, Martín-de-carpi J, De Ridder L, Fagerberg U, Hugot J, Kierkus J, Kolacek S, Koletzko S, Lionetti P, Miele E, Navas López V, Paerregaard A, Russell R, Serban D, Shaoul R, Van Rheenen P, Veereman G, Weiss B, Wilson D, Dignass A, Eliakim A, Winter H, Turner D. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. Journal of Crohn's and Colitis 2014;8:1179-207. [DOI: 10.1016/j.crohns.2014.04.005] [Cited by in Crossref: 580] [Cited by in F6Publishing: 463] [Article Influence: 82.9] [Reference Citation Analysis]
16 Ha C, Kornbluth A. Mucosal healing in inflammatory bowel disease: where do we stand? Curr Gastroenterol Rep. 2010;12:471-478. [PMID: 20886319 DOI: 10.1007/s11894-010-0146-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 3.1] [Reference Citation Analysis]
17 Lakatos PL, Kiss LS. Is the disease course predictable in inflammatory bowel diseases? World J Gastroenterol. 2010;16:2591-2599. [PMID: 20518079 DOI: 10.3748/wjg.v16.i21.2591.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Bermejo F, Gisbert JP. Usefulness of salicylate and thiopurine coprescription in steroid-dependent ulcerative colitis and withdrawal strategies. Ther Adv Chronic Dis 2010;1:107-14. [PMID: 23251733 DOI: 10.1177/2040622310374897] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
19 Panaccione R, Hibi T, Peyrin-Biroulet L, Schreiber S. Implementing changes in clinical practice to improve the management of Crohn’s disease. J Crohns Colitis. 2012;6 Suppl 2:S235-S242. [PMID: 22463930 DOI: 10.1016/s1873-9946(12)60503-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
20 Goel RM, Blaker P, Mentzer A, Fong SC, Marinaki AM, Sanderson JD. Optimizing the use of thiopurines in inflammatory bowel disease. Ther Adv Chronic Dis. 2015;6:138-146. [PMID: 25954498 DOI: 10.1177/2040622315579063] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
21 Dignass A, Van Assche G, Lindsay J, Lémann M, Söderholm J, Colombel J, Danese S, D'hoore A, Gassull M, Gomollón F, Hommes D, Michetti P, O'morain C, Öresland T, Windsor A, Stange E, Travis S. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. Journal of Crohn's and Colitis 2010;4:28-62. [DOI: 10.1016/j.crohns.2009.12.002] [Cited by in Crossref: 981] [Cited by in F6Publishing: 872] [Article Influence: 89.2] [Reference Citation Analysis]
22 Smith MA, Irving PM, Marinaki AM, Sanderson JD. Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease. Aliment Pharmacol Ther. 2010;32:119-130. [PMID: 20412066 DOI: 10.1111/j.1365-2036.2010.04330.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 63] [Article Influence: 5.9] [Reference Citation Analysis]
23 Martin A, Nachury M, Peyrin-biroulet L, Bouhnik Y, Nancey S, Bourrier A, Serrero M, Fumery M, Buisson A, Laharie D, Gilletta C, Filippi J, Allez M, Bouguen G, Roblin X, Altwegg R, Dib N, Pineton de Chambrun G, Savoye G, Carbonnel F, Viennot S, Amiot A, Amiot A, Martin A, Gagnière C, Nachury M, Pariente B, Wils P, Peyrin-biroulet L, Zallot C, Bouhnik Y, Treton X, Stefanescu C, Nancey S, Boschetti G, Seksik P, Beaugerie L, Kirchgesner J, Bourrier A, Sokol H, Serrero M, Fumery M, Yzet C, Brazier F, Laharie D, Rivière P, Poullenot F, Buisson A, Gilletta C, Filippi J, Hebuterne X, Allez M, Gornet J, Bouguen G, Siproudhis L, Roblin X, Altwegg R, Pineton de Chambrun G, Dib N, Savoye G, Carbonnel F, Meyer A, Viennot S, Lebaut G; GETAID-Vedo-STOP Study Group. Maintenance of Remission Among Patients With Inflammatory Bowel Disease After Vedolizumab Discontinuation: A Multicentre Cohort Study. Journal of Crohn's and Colitis 2020;14:896-903. [DOI: 10.1093/ecco-jcc/jjaa005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
24 Jung YS, Cheon JH, Hong SP, Kim TI, Kim WH. Clinical outcomes and prognostic factors for thiopurine maintenance therapy in patients with intestinal Behcet’s disease. Inflamm Bowel Dis. 2012;18:750-757. [PMID: 21618352 DOI: 10.1002/ibd.21757] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
25 Cornish JS, Wirthgen E, Däbritz J. Biomarkers Predictive of Response to Thiopurine Therapy in Inflammatory Bowel Disease.Front Med (Lausanne). 2020;7:8. [PMID: 32064265 DOI: 10.3389/fmed.2020.00008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
26 Szamosi T, Banai J, Lakatos L, Czegledi Z, David G, Zsigmond F, Pandur T, Erdelyi Z, Gemela O, Papp M. Early azathioprine/biological therapy is associated with decreased risk for first surgery and delays time to surgery but not reoperation in both smokers and nonsmokers with Crohn’s disease, while smoking decreases the risk of colectomy in ulcerative colitis. Eur J Gastroenterol Hepatol. 2010;22:872-879. [PMID: 19648821 DOI: 10.1097/meg.0b013e32833036d9] [Cited by in Crossref: 44] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
27 Frias Gomes C, Chapman TP, Satsangi J. De-escalation of medical therapy in inflammatory bowel disease. Curr Opin Pharmacol 2020;55:73-81. [PMID: 33160250 DOI: 10.1016/j.coph.2020.09.014] [Reference Citation Analysis]
28 Ferrante M, Karmiris K, Newnham E, Siffledeen J, Zelinkova Z, van Assche G, Lakatos PL, Panés J, Sturm A, Travis S, van der Woude CJ, Reinisch W, Colombel J, Panaccione R. Physician perspectives on unresolved issues in the use of conventional therapy in Crohn's disease: Results from an international survey and discussion programme. Journal of Crohn's and Colitis 2012;6:116-31. [DOI: 10.1016/j.crohns.2011.09.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
29 Onal IK, Beyazit Y, Altinbas A, Kurt M, Arhan M. Maintenance therapy for Crohn's disease: should it be indefinite? Eur J Gastroenterol Hepatol. 2015; Jul 15. [Epub ahead of print]. [PMID: 26181109 DOI: 10.1097/MEG.0000000000000433] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
30 Doherty G, Katsanos KH, Burisch J, Allez M, Papamichael K, Stallmach A, Mao R, Berset IP, Gisbert JP, Sebastian S, Kierkus J, Lopetuso L, Szymanska E, Louis E. European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal ['Exit Strategies'] in Inflammatory Bowel Disease. J Crohns Colitis. 2018;12:17-31. [PMID: 28981623 DOI: 10.1093/ecco-jcc/jjx101] [Cited by in Crossref: 71] [Cited by in F6Publishing: 57] [Article Influence: 23.7] [Reference Citation Analysis]
31 Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H;  IBD guidelines eDelphi consensus group; Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68:s1-s106. [PMID: 31562236 DOI: 10.1136/gutjnl-2019-318484] [Cited by in Crossref: 361] [Cited by in F6Publishing: 290] [Article Influence: 180.5] [Reference Citation Analysis]
32 Louis E. Immunosuppressant combined with infliximab in Crohn's Disease: for 6 months, for 2 years, or forever? Inflamm Bowel Dis. 2011;17:858-859. [PMID: 20593432 DOI: 10.1002/ibd.21407] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
33 Kwak MS, Kim KJ, Cheon JH, Kim WS, Lee JM, Hwang SW, Park SH, Yang DH, Ye BD, Byeon JS, Myung SJ, Yang SK. Comparison of Concomitant Mesalamine and Immunomodulator Therapy and Immunomodulator Monotherapy for Crohn's Disease. Gastroenterol Res Pract 2018;2018:4826973. [PMID: 29576767 DOI: 10.1155/2018/4826973] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
34 Landerholm K, Kalman D, Wallon C, Myrelid P. Immunomodulators: Friends or Enemies in Surgery for Crohn’s Disease? CDT 2019;20:1384-98. [DOI: 10.2174/1389450120666190617163919] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
35 Bewtra M. Lymphoma in Inflammatory Bowel Disease and Treatment Decisions. American Journal of Gastroenterology 2012;107:964-70. [DOI: 10.1038/ajg.2011.479] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
36 Lakatos PL, Czegledi Z, Szamosi T, Banai J, David G, Zsigmond F, Pandur T, Erdelyi Z, Gemela O, Papp J. Perianal disease, small bowel disease, smoking, prior steroid or early azathioprine/biological therapy are predictors of disease behavior change in patients with Crohn's disease. World J Gastroenterol. 2009;15:3504-3510. [PMID: 19630105 DOI: 10.3748/wjg.15.3504.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Annaházi A, Molnár T. Optimal Endpoint of Therapy in IBD: An Update on Factors Determining a Successful Drug Withdrawal. Gastroenterol Res Pract 2015;2015:832395. [PMID: 26199624 DOI: 10.1155/2015/832395] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
38 Kennedy NA, Kalla R, Warner B, Gambles CJ, Musy R, Reynolds S, Dattani R, Nayee H, Felwick R, Harris R, Marriott S, Senanayake SM, Lamb CA, Al-Hilou H, Gaya DR, Irving PM, Mansfield J, Parkes M, Ahmad T, Cummings JR, Arnott ID, Satsangi J, Lobo AJ, Smith M, Lindsay JO, Lees CW. Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients. Aliment Pharmacol Ther 2014;40:1313-23. [PMID: 25284134 DOI: 10.1111/apt.12980] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 5.1] [Reference Citation Analysis]
39 Pariente B, Laharie D. Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases. Aliment Pharmacol Ther. 2014;40:338-353. [PMID: 24957164 DOI: 10.1111/apt.12838] [Cited by in Crossref: 66] [Cited by in F6Publishing: 53] [Article Influence: 9.4] [Reference Citation Analysis]
40 Gisbert JP. Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding. Inflamm Bowel Dis. 2010;16:881-895. [PMID: 19885906 DOI: 10.1002/ibd.21154] [Cited by in Crossref: 102] [Cited by in F6Publishing: 78] [Article Influence: 9.3] [Reference Citation Analysis]
41 Clarke K, Regueiro M. Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission. Inflamm Bowel Dis. 2012;18:174-179. [PMID: 21674731 DOI: 10.1002/ibd.21792] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 3.6] [Reference Citation Analysis]
42 Sparrow MP, Melmed GY, Devlin S, Kozuch P, Raffals L, Loftus Jr EV, Rubin DT, Spiegel B, Baidoo L, Bressler B, Cheifetz A, Irving P, Jones J, Kaplan GG, Velayos F, Siegel CA. De‐escalating medical therapy in Crohn’s disease patients who are in deep remission: A RAND appropriateness panel. GastroHep 2019;1:108-17. [DOI: 10.1002/ygh2.337] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
43 Mantzaris GJ. Thiopurines and Methotrexate Use in IBD Patients in a Biologic Era. Curr Treat Options Gastro 2017;15:84-104. [DOI: 10.1007/s11938-017-0128-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
44 Kapur S, Hanauer SB. The Evolving Role of Thiopurines in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol 2019;17:420-33. [PMID: 31352659 DOI: 10.1007/s11938-019-00244-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
45 Burger D, Travis S. Conventional Medical Management of Inflammatory Bowel Disease. Gastroenterology 2011;140:1827-1837.e2. [DOI: 10.1053/j.gastro.2011.02.045] [Cited by in Crossref: 135] [Cited by in F6Publishing: 118] [Article Influence: 13.5] [Reference Citation Analysis]
46 Camus M, Seksik P, Bourrier A, Nion-Larmurier I, Sokol H, Baumer P, Beaugerie L, Cosnes J. Long-term outcome of patients with Crohn's disease who respond to azathioprine. Clin Gastroenterol Hepatol. 2013;11:389-394. [PMID: 23142207 DOI: 10.1016/j.cgh.2012.10.038] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 5.3] [Reference Citation Analysis]
47 Chande N, Patton PH, Tsoulis DJ, Thomas BS, MacDonald JK. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2015;CD000067. [PMID: 26517527 DOI: 10.1002/14651858.cd000067.pub3] [Cited by in Crossref: 42] [Cited by in F6Publishing: 52] [Article Influence: 7.0] [Reference Citation Analysis]
48 Kiss LS, Lakatos PL. Prediction of the disease course in inflammatory bowel diseases. Orvosi Hetilap 2010;151:293-301. [DOI: 10.1556/oh.2010.28813] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
49 Bermejo F, Aguas M, Chaparro M, Domènech E, Echarri A, García-Planella E, Guerra I, Gisbert JP, López-Sanromán A; en representación de GETECCU. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of thiopurines in inflammatory bowel disease. Gastroenterol Hepatol 2018;41:205-21. [PMID: 29357999 DOI: 10.1016/j.gastrohep.2017.11.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 5.3] [Reference Citation Analysis]
50 Goldberg R, Irving PM. Toxicity and response to thiopurines in patients with inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2015;9:891-900. [PMID: 25915575 DOI: 10.1586/17474124.2015.1039987] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
51 Sunseri W, Hyams JS, Lerer T, Mack DR, Griffiths AM, Otley AR, Rosh JR, Carvalho R, Grossman AB, Cabrera J, Pfefferkorn MD, Rick J, Leleiko NS, Hitch MC, Oliva-hemker M, Saeed SA, Kappelman M, Markowitz J, Keljo DJ. Retrospective Cohort Study of Methotrexate Use in the Treatment of Pediatric Crohnʼs Disease: . Inflammatory Bowel Diseases 2014;20:1341-5. [DOI: 10.1097/mib.0000000000000102] [Cited by in Crossref: 25] [Cited by in F6Publishing: 4] [Article Influence: 3.6] [Reference Citation Analysis]
52 Cassinotti A, Actis GC, Duca P, Massari A, Colombo E, Gai E, Annese V, D'albasio G, Manes G, Travis S, Porro GB, Ardizzone S. Maintenance Treatment With Azathioprine in Ulcerative Colitis: Outcome and Predictive Factors After Drug Withdrawal. Am J Gastroenterol 2009;104:2760-7. [DOI: 10.1038/ajg.2009.410] [Cited by in Crossref: 81] [Cited by in F6Publishing: 68] [Article Influence: 6.8] [Reference Citation Analysis]
53 Gisbert JP, Chaparro M, Gomollón F. Common misconceptions about 5-aminosalicylates and thiopurines in inflammatory bowel disease. World J Gastroenterol 2011; 17(30): 3467-3478 [PMID: 21941413 DOI: 10.3748/wjg.v17.i30.3467] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
54 Ha C, Dassopoulos T. Thiopurine therapy in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2010;4:575-588. [PMID: 20932143 DOI: 10.1586/egh.10.59] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
55 Ooi CJ, Hilmi I, Banerjee R, Chuah SW, Ng SC, Wei SC, Makharia GK, Pisespongsa P, Chen MH, Ran ZH, Ye BD, Park DI, Ling KL, Ong D, Ahuja V, Goh KL, Sollano J, Lim WC, Leung WK, Ali RAR, Wu DC, Ong E, Mustaffa N, Limsrivilai J, Hisamatsu T, Yang SK, Ouyang Q, Geary R, De Silva JH, Rerknimitr R, Simadibrata M, Abdullah M, Leong RWL; Asia-Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease and Asian Organization for Crohn's and Colitis. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. J Gastroenterol Hepatol 2019;34:1296-315. [PMID: 30848854 DOI: 10.1111/jgh.14648] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 7.5] [Reference Citation Analysis]
56 Korelitz BI, Reddy B, Bratcher J. Desensitization of patients with allergic reactions to immunosuppressives in the treatment of inflammatory bowel disease. Expert Opin Drug Saf 2010;9:379-82. [PMID: 20367524 DOI: 10.1517/14740330903571626] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
57 Peyrin-biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, D'haens G, Dotan I, Dubinsky M, Feagan B, Fiorino G, Gearry R, Krishnareddy S, Lakatos PL, Loftus EV, Marteau P, Munkholm P, Murdoch TB, Ordás I, Panaccione R, Riddell RH, Ruel J, Rubin DT, Samaan M, Siegel CA, Silverberg MS, Stoker J, Schreiber S, Travis S, Van Assche G, Danese S, Panes J, Bouguen G, O'donnell S, Pariente B, Winer S, Hanauer S, Colombel J-. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. American Journal of Gastroenterology 2015;110:1324-38. [DOI: 10.1038/ajg.2015.233] [Cited by in Crossref: 937] [Cited by in F6Publishing: 810] [Article Influence: 156.2] [Reference Citation Analysis]
58 Nielsen OH, Bjerrum JT, Herfarth H, Rogler G. Recent advances using immunomodulators for inflammatory bowel disease. J Clin Pharmacol. 2013;53:575-588. [PMID: 23408468 DOI: 10.1002/jcph.2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
59 Higgins PD. New keys to maintenance treatment in ulcerative colitis. Dig Dis 2010;28:483-9. [PMID: 20926876 DOI: 10.1159/000320406] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
60 Louis E. Tailoring Biologic or Immunomodulator Treatment Withdrawal in Inflammatory Bowel Disease. Front Med (Lausanne) 2019;6:302. [PMID: 31970158 DOI: 10.3389/fmed.2019.00302] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
61 Hirten RP, Lakatos PL, Halfvarson J, Colombel JF. A User's Guide to De-escalating Immunomodulator and Biologic Therapy in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol 2020;18:1336-45. [PMID: 31887444 DOI: 10.1016/j.cgh.2019.12.019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
62 Beigel F, Steinborn A, Schnitzler F, Tillack C, Breiteneicher S, John JM, Van Steen K, Laubender RP, Göke B, Seiderer J, Brand S, Ochsenkühn T. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies. Pharmacoepidemiol Drug Saf 2014;23:735-44. [PMID: 24788825 DOI: 10.1002/pds.3621] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 6.7] [Reference Citation Analysis]
63 Cintolo M, Costantino G, Pallio S, Fries W. Mucosal healing in inflammatory bowel disease: Maintain or de-escalate therapy. World J Gastrointest Pathophysiol 2016; 7(1): 1-16 [PMID: 26909224 DOI: 10.4291/wjgp.v7.i1.1] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
64 Mottet C, Schoepfer AM, Juillerat P, Cosnes J, Froehlich F, Kessler-brondolo V, Seibold F, Rogler G, Vavricka SR, Michetti P. Experts Opinion on the Practical Use of Azathioprine and 6-Mercaptopurine in Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 2016;22:2733-47. [DOI: 10.1097/mib.0000000000000923] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 3.2] [Reference Citation Analysis]
65 Meredith J, Henderson P, Wilson DC, Russell RK. Combination Immunotherapy Use and Withdrawal in Pediatric Inflammatory Bowel Disease-A Review of the Evidence. Front Pediatr 2021;9:708310. [PMID: 34621712 DOI: 10.3389/fped.2021.708310] [Reference Citation Analysis]
66 van Asseldonk DP, Sanderson J, de Boer NK, Sparrow MP, Lémann M, Ansari A, Almer SH, Florin TH, Gearry RB, Mulder CJ. Difficulties and possibilities with thiopurine therapy in inflammatory bowel disease--proceedings of the first Thiopurine Task Force meeting. Dig Liver Dis. 2011;43:270-276. [PMID: 20934926 DOI: 10.1016/j.dld.2010.09.001] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
67 Kwon JH, Im JP, Ye BD, Cheon JH, Jang HJ, Lee KM, Kim YS, Kim SW, Kim YH, Song GA, Han DS, Kim WH, Kim JS. Disease Phenotype, Activity and Clinical Course Prediction Based on C-Reactive Protein Levels at Diagnosis in Patients with Crohn's Disease: Results from the CONNECT Study. Gut Liver 2016;10:595-603. [PMID: 27021506 DOI: 10.5009/gnl15411] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
68 Ooi CJ, Hilmi I, Banerjee R, Chuah SW, Ng SC, Wei SC, Makharia GK, Pisespongsa P, Chen MH, Ran ZH, Ye BD, Park DI, Ling KL, Ong D, Ahuja V, Goh KL, Sollano J, Lim WC, Leung WK, Ali RAR, Wu DC, Ong E, Mustaffa N, Limsrivilai J, Hisamatsu T, Yang SK, Ouyang Q, Geary R, De Silva JH, Rerknimitr R, Simadibrata M, Abdullah M, Leong RW; Asia Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease and Asian Organization for Crohn’s and Colitis. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. Intest Res 2019;17:285-310. [PMID: 31146509 DOI: 10.5217/ir.2019.00026] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 15.0] [Reference Citation Analysis]
69 Torres J, Boyapati RK, Kennedy NA, Louis E, Colombel JF, Satsangi J. Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease. Gastroenterology. 2015;149:1716-1730. [PMID: 26381892 DOI: 10.1053/j.gastro.2015.08.055] [Cited by in Crossref: 119] [Cited by in F6Publishing: 108] [Article Influence: 19.8] [Reference Citation Analysis]
70 Moreno-Rincón E, Benítez JM, Serrano-Ruiz FJ, Vázquez-Morón JM, Pallarés-Manrique H, Herrera-Justiniano JM, Leo-Carnerero E, Gómez-García MR, Cabello-Tapia MJ, Castro-Fernández M. Prognosis of Patients with Ulcerative Colitis in Sustained Remission After Thiopurines Withdrawal. Inflamm Bowel Dis. 2015;21:1564-1571. [PMID: 26070002 DOI: 10.1097/mib.0000000000000400] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
71 Wenzl HH, Primas C, Novacek G, Teml A, Öfferlbauer-Ernst A, Högenauer C, Vogelsang H, Petritsch W, Reinisch W. Withdrawal of long-term maintenance treatment with azathioprine tends to increase relapse risk in patients with Crohn's disease. Dig Dis Sci 2015;60:1414-23. [PMID: 25381202 DOI: 10.1007/s10620-014-3419-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
72 Iborra M, Herreras J, Boscá-Watts MM, Cortés X, Trejo G, Cerrillo E, Hervás D, Mínguez M, Beltrán B, Nos P. Withdrawal of Azathioprine in Inflammatory Bowel Disease Patients Who Sustain Remission: New Risk Factors for Relapse. Dig Dis Sci 2019;64:1612-21. [PMID: 30604371 DOI: 10.1007/s10620-018-5429-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
73 Ye BD, Yang S, Shin SJ, Lee KM, Jang BI, Cheon JH, Choi CH, Kim Y, Lee H; IBD Study Group of the Korean Association for the Study of the Intestinal Diseases. Guidelines for the Management of Crohn's Disease. Intest Res 2012;10:26. [DOI: 10.5217/ir.2012.10.1.26] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
74 Ince MN, Elliott DE. Effective Use of the Laboratory in the Management of Patients with Inflammatory Bowel Diseases. Gastroenterol Clin North Am 2019;48:237-58. [PMID: 31046973 DOI: 10.1016/j.gtc.2019.02.006] [Reference Citation Analysis]
75 Simon M, Pariente B, Lambert J, Cosnes J, Bouhnik Y, Marteau P, Allez M, Colombel JF, Gornet JM. Long-term Outcomes of Thalidomide Therapy for Adults With Refractory Crohn's Disease. Clin Gastroenterol Hepatol 2016;14:966-972.e2. [PMID: 26598226 DOI: 10.1016/j.cgh.2015.10.034] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
76 Lakatos PL, Kiss LS. Current status of thiopurine analogues in the treatment in Crohn's disease. World J Gastroenterol 2011; 17(39): 4372-4381 [PMID: 22110262 DOI: 10.3748/wjg.v17.i39.4372] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
77 Oussalah A, Chevaux JB, Fay R, Sandborn WJ, Bigard MA, Peyrin-Biroulet L. Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy. Am J Gastroenterol. 2010;105:1142-1149. [PMID: 20389296 DOI: 10.1038/ajg.2010.158] [Cited by in Crossref: 70] [Cited by in F6Publishing: 59] [Article Influence: 6.4] [Reference Citation Analysis]
78 Actis GC, Pellicano R, Rizzetto M, Ayoubi M, Leone N, Tappero G, Pazienza P, Rosina F. Individually administered or co-prescribed thiopurines and mesalamines for inflammatory bowel disease. World J Gastroenterol 2009; 15(12): 1420-1426 [PMID: 19322913 DOI: 10.3748/wjg.15.1420] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
79 Walsh AJ, Bryant RV, Travis SP. Current best practice for disease activity assessment in IBD. Nat Rev Gastroenterol Hepatol. 2016;13:567-579. [PMID: 27580684 DOI: 10.1038/nrgastro.2016.128] [Cited by in Crossref: 90] [Cited by in F6Publishing: 84] [Article Influence: 18.0] [Reference Citation Analysis]
80 Peyrin-Biroulet L, Gonzalez F, Dubuquoy L, Rousseaux C, Dubuquoy C, Decourcelle C, Saudemont A, Tachon M, Béclin E, Odou MF. Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn’s disease. Gut. 2012;61:78-85. [PMID: 21940721 DOI: 10.1136/gutjnl-2011-300370] [Cited by in Crossref: 151] [Cited by in F6Publishing: 143] [Article Influence: 15.1] [Reference Citation Analysis]
81 Pittet V, Froehlich F, Maillard MH, Mottet C, Gonvers JJ, Felley C, Vader JP, Burnand B, Michetti P, Schoepfer A. When do we dare to stop biological or immunomodulatory therapy for Crohn’s disease? Results of a multidisciplinary European expert panel. J Crohns Colitis. 2013;7:820-826. [PMID: 23664620 DOI: 10.1016/j.crohns.2013.04.013] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 4.9] [Reference Citation Analysis]
82 Gomollón F, Gisbert JP. [Must immunomodulators be added to biological treatment in inflammatory bowel disease?]. Gastroenterol Hepatol 2010;33:43-53. [PMID: 19616870 DOI: 10.1016/j.gastrohep.2009.03.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
83 Kirchgesner J, Lemaitre M, Rudnichi A, Racine A, Zureik M, Carbonnel F, Dray-spira R. Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases 2009-2014. Aliment Pharmacol Ther 2017;45:37-49. [DOI: 10.1111/apt.13835] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 9.2] [Reference Citation Analysis]
84 Armuzzi A, Van Assche G, Reinisch W, de Chambrun GP, Griffiths A, Sladek M, Preiss JC, Lukas M, D'haens G. Results of the 2nd scientific workshop of the ECCO (IV): Therapeutic strategies to enhance intestinal healing in inflammatory bowel disease. Journal of Crohn's and Colitis 2012;6:492-502. [DOI: 10.1016/j.crohns.2011.12.016] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
85 Louis E, Irving P, Beaugerie L. Use of azathioprine in IBD: modern aspects of an old drug. Gut 2014;63:1695-9. [PMID: 24943205 DOI: 10.1136/gutjnl-2013-306711] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
86 Sokol H, Seksik P, Nion-Larmurier I, Vienne A, Beaugerie L, Cosnes J. Current smoking, not duration of remission, delays Crohn's disease relapse following azathioprine withdrawal. Inflamm Bowel Dis 2010;16:362-3. [PMID: 19462422 DOI: 10.1002/ibd.20981] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
87 Higgins PDR. Who Wants to Take a Thiopurine Holiday? American Journal of Gastroenterology 2011;106:556-8. [DOI: 10.1038/ajg.2010.483] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
88 Chapman TP, Gomes CF, Louis E, Colombel J, Satsangi J. De-escalation of immunomodulator and biological therapy in inflammatory bowel disease. The Lancet Gastroenterology & Hepatology 2020;5:63-79. [DOI: 10.1016/s2468-1253(19)30186-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 16.0] [Reference Citation Analysis]
89 Dart RJ, Irving PM. Optimising use of thiopurines in inflammatory bowel disease. Expert Review of Clinical Immunology 2017;13:877-88. [DOI: 10.1080/1744666x.2017.1351298] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 2.3] [Reference Citation Analysis]
90 Lin MV, Blonski W, Lichtenstein GR. What is the optimal therapy for Crohn‘s disease: step-up or top-down? Expert Rev Gastroenterol Hepatol. 2010;4:167-180. [PMID: 20350264 DOI: 10.1586/egh.10.4] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
91 高树娟, 施瑞华. 炎症性肠病治疗的新进展. 世界华人消化杂志 2012; 20(36): 3742-3747 [DOI: 10.11569/wcjd.v20.i36.3742] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
92 Lakatos PL, Kiss LS. Is the disease course predictable in inflammatory bowel diseases? World J Gastroenterol 2010; 16(21): 2591-2599 [PMID: 20518079 DOI: 10.3748/wjg.v16.i21.2591] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
93 Benitez JM, Meuwis MA, Reenaers C, Van Kemseke C, Meunier P, Louis E. Role of endoscopy, cross-sectional imaging and biomarkers in Crohn’s disease monitoring. Gut. 2013;62:1806-1816. [PMID: 24203056 DOI: 10.1136/gutjnl-2012-303957] [Cited by in Crossref: 70] [Cited by in F6Publishing: 58] [Article Influence: 10.0] [Reference Citation Analysis]
94 罗凤燕, 白爱平. 硫唑嘌呤治疗炎症性肠病诱发淋巴瘤. 世界华人消化杂志 2013; 21(22): 2121-2127 [DOI: 10.11569/wcjd.v21.i22.2121] [Reference Citation Analysis]
95 Barnes EL, Burakoff R. New Biomarkers for Diagnosing Inflammatory Bowel Disease and Assessing Treatment Outcomes. Inflamm Bowel Dis 2016;22:2956-65. [PMID: 27763951 DOI: 10.1097/MIB.0000000000000903] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 5.7] [Reference Citation Analysis]
96 Florin THJ, Wright JD, Jambhrunkar SD, Henman MG, Popat A. A well-tolerated and rapidly acting thiopurine for IBD? Drug Discov Today 2019;24:37-41. [PMID: 30196006 DOI: 10.1016/j.drudis.2018.09.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
97 Gionchetti P, Calabrese C, Tambasco R, Brugnera R, Straforini G, Liguori G, Fornarini GS, Riso D, Campieri M, Rizzello F. Role of conventional therapies in the era of biological treatment in Crohn’s disease. World J Gastroenterol 2011; 17(14): 1797-1806 [PMID: 21528051 DOI: 10.3748/wjg.v17.i14.1797] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
98 Murdoch T, O'Donnell S, Silverberg MS, Panaccione R. Biomarkers as potential treatment targets in inflammatory bowel disease: A systematic review. Can J Gastroenterol Hepatol 2015;29:203-8. [PMID: 25965441 DOI: 10.1155/2015/389548] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
99 Lee KM, Kim YS, Seo GS, Kim TO, Yang SK; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Use of Thiopurines in Inflammatory Bowel Disease: A Consensus Statement by the Korean Association for the Study of Intestinal Diseases (KASID). Intest Res. 2015;13:193-207. [PMID: 26130993 DOI: 10.5217/ir.2015.13.3.193] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 6.5] [Reference Citation Analysis]
100 Jourdil N, Fonrose X, Boulieu R, Stanke-Labesque F; pour le groupe Suivi Thérapeutique Pharmacologique de la Société Française de Pharmacologie et de Thérapeutique. [Not Available]. Therapie 2010;65:177-86. [PMID: 27392984 DOI: 10.2515/therapie/2010030] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
101 Triantafillidis JK, Merikas E, Georgopoulos F. Current and emerging drugs for the treatment of inflammatory bowel disease. Drug Des Devel Ther. 2011;5:185-210. [PMID: 21552489 DOI: 10.2147/dddt.s11290] [Cited by in Crossref: 137] [Cited by in F6Publishing: 76] [Article Influence: 13.7] [Reference Citation Analysis]
102 Cheifetz AS. Management of active Crohn disease. JAMA 2013;309:2150-8. [PMID: 23695484 DOI: 10.1001/jama.2013.4466] [Cited by in Crossref: 72] [Cited by in F6Publishing: 55] [Article Influence: 9.0] [Reference Citation Analysis]
103 Reenaers C, Mary JY, Nachury M, Bouhnik Y, Laharie D, Allez M, Fumery M, Amiot A, Savoye G, Altwegg R, Devos M, Malamut G, Bourreille A, Flourie B, Marteau P, Vuitton L, Coffin B, Viennot S, Lambert J, Colombel JF, Louis E; Groupe d'Etude Therapeutique des Affections Inflammatoires du tube Digestif. Outcomes 7 Years After Infliximab Withdrawal for Patients With Crohn's Disease in Sustained Remission. Clin Gastroenterol Hepatol. 2018;16:234-243.e2. [PMID: 28993262 DOI: 10.1016/j.cgh.2017.09.061] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 10.3] [Reference Citation Analysis]
104 Alexander DB, Iigo M, Abdelgied M, Ozeki K, Tanida S, Joh T, Takahashi S, Tsuda H. Bovine lactoferrin and Crohn's disease: a case study. Biochem Cell Biol 2017;95:133-41. [PMID: 28165294 DOI: 10.1139/bcb-2016-0107] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
105 Dassopoulos T, Sninsky CA. Optimizing Immunomodulators and Anti-TNF Agents in the Therapy of Crohn Disease. Gastroenterology Clinics of North America 2012;41:393-409. [DOI: 10.1016/j.gtc.2012.01.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
106 van den Bosch BJ, Coenen MJ. Pharmacogenetics of inflammatory bowel disease. Pharmacogenomics 2021;22:55-66. [PMID: 33305616 DOI: 10.2217/pgs-2020-0095] [Reference Citation Analysis]